127 related articles for article (PubMed ID: 34969346)
1. Prognostic impact of micromegakaryocytes in primary myelodysplastic syndromes.
Saumell S; Fernández-Serrano M; Mesa A; López-Cadenas F; Arenillas L; Alfonso A; Montoro MJ; Molero A; Leoz P; Riego V; Gallur L; Salamero O; Navarrete M; Tazón-Vega B; Ortega M; Reig Ò; Roué G; Calvo X; Prosper F; Díez-Campelo M; Valcárcel D
Leuk Lymphoma; 2022 May; 63(5):1227-1235. PubMed ID: 34969346
[TBL] [Abstract][Full Text] [Related]
2. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group.
Papageorgiou SG; Vasilatou D; Kontos CK; Kotsianidis I; Symeonidis A; Galanopoulos AG; Hatzimichael E; Megalakaki A; Poulakidas E; Diamantopoulos P; Vassilakopoulos TP; Zikos P; Papadaki H; Mparmparousi D; Bouronikou E; Panayiotidis P; Viniou NA; Pappa V
Am J Hematol; 2018 Jul; 93(7):895-901. PubMed ID: 29659040
[TBL] [Abstract][Full Text] [Related]
4. [Allo-HSCT for acute myeloid leukemia with myelodysplastic-related changes: a clinical analysis].
Zhang HX; Pang AM; Chen X; Zhang RL; Zhai WH; Ma QL; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):814-822. PubMed ID: 34788920
[No Abstract] [Full Text] [Related]
5. Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index.
van Spronsen MF; Ossenkoppele GJ; Holman R; van de Loosdrecht AA
Eur J Cancer; 2014 Dec; 50(18):3198-205. PubMed ID: 25454415
[TBL] [Abstract][Full Text] [Related]
6. Validation of the Revised International Prognostic Scoring System for patients with myelodysplastic syndromes.
Savic A; Marisavljevic D; Kvrgic V; Stanisavljevic N
Acta Haematol; 2014; 131(4):231-8. PubMed ID: 24335346
[TBL] [Abstract][Full Text] [Related]
7. A review of therapy-related myelodysplastic syndromes and acute myeloid leukaemia (t-MDS/AML) in Irish patients: a single centre experience.
Maung SW; Burke C; Hayde J; Walshe J; McDermott R; Desmond R; McHugh J; Enright H
Hematology; 2017 Jul; 22(6):341-346. PubMed ID: 28196450
[TBL] [Abstract][Full Text] [Related]
8. [Risk factors for leukemia transformation in patients with myelodysplastic syndromes].
Zhao SY; Xu ZF; Qin TJ; Qu SQ; Li CW; Jia YJ; Pan LJ; Li B; Gao QY; Jiao M; Huang HJ; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2022 Oct; 43(10):818-825. PubMed ID: 36709195
[No Abstract] [Full Text] [Related]
9. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
Steensma DP; Abedi M; Bejar R; Cogle CR; Foucar K; Garcia-Manero G; George TI; Grinblatt D; Komrokji R; Ma X; Maciejewski J; Pollyea DA; Savona MR; Scott B; Sekeres MA; Thompson MA; Swern AS; Nifenecker M; Sugrue MM; Erba H
BMC Cancer; 2016 Aug; 16():652. PubMed ID: 27538433
[TBL] [Abstract][Full Text] [Related]
10. Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromes.
Balleari E; Salvetti C; Del Corso L; Filiberti R; Bacigalupo A; Bellodi A; Beltrami G; Bergamaschi M; Berisso G; Calzamiglia T; Carella AM; Cavalleri M; Da Col A; Favorini S; Forni GL; Goretti R; Miglino M; Mitscheuning L; Molinari E; Racchi O; Scudeletti M; Tassara R; Gobbi M; Lemoli R; Clavio M
Leuk Res; 2015 Aug; 39(8):846-52. PubMed ID: 26145790
[TBL] [Abstract][Full Text] [Related]
11. Are micromegakaryocytes specific for refractory cytopenia of childhood (RCC)? A study of 38 pediatric patients with thrombocytopenia unrelated to RCC.
Aqil B; Punia JN; Curry CV; Marcogliese AN; Elghetany MT
Leuk Res; 2016 Aug; 47():84-7. PubMed ID: 27285854
[TBL] [Abstract][Full Text] [Related]
12. A retrospective validation of the IPSS-M molecular score in primary and therapy-related myelodysplastic syndromes (MDS).
Sabile JMG; Kaempf A; Tomic K; Manu GP; Swords R; Migdady Y
Leuk Lymphoma; 2023 Oct; 64(10):1689-1694. PubMed ID: 37440338
[TBL] [Abstract][Full Text] [Related]
13. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.
Voso MT; Fenu S; Latagliata R; Buccisano F; Piciocchi A; Aloe-Spiriti MA; Breccia M; Criscuolo M; Andriani A; Mancini S; Niscola P; Naso V; Nobile C; Piccioni AL; D'Andrea M; D'Addosio A; Leone G; Venditti A
J Clin Oncol; 2013 Jul; 31(21):2671-7. PubMed ID: 23796988
[TBL] [Abstract][Full Text] [Related]
14. Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes.
Papageorgiou SG; Kotsianidis I; Bouchla A; Symeonidis A; Galanopoulos A; Viniou NA; Hatzimichael E; Vassilakopoulos TP; Gogos D; Megalakaki A; Zikos P; Diamantopoulos P; Kourakli A; Giannoulia P; Papoutselis M; Poulakidas E; Arapaki M; Vardi A; Anagnostopoulos A; Mparmparousi D; Papaioannou M; Bouronikou E; Dimou M; Papadaki H; Panayiotidis P; Pappa V
Ther Adv Hematol; 2020; 11():2040620720966121. PubMed ID: 33343854
[TBL] [Abstract][Full Text] [Related]
15. Clinical Prognostic Factors in 86 Chinese Patients with Primary Myelodysplastic Syndromes and Trisomy 8: A Single Institution Experience.
Yue QF; Chen L; She XM; Hu B; Hu Y; Zou P; Liu XY
Yonsei Med J; 2016 Mar; 57(2):358-64. PubMed ID: 26847287
[TBL] [Abstract][Full Text] [Related]
16. The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes.
Duong VH; Padron E; Al Ali NH; Lancet JE; Hall J; Kwok B; Zhang L; Epling-Burnette PK; List AF; Komrokji RS
Ann Hematol; 2018 Feb; 97(2):247-254. PubMed ID: 29167940
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of U2AF1 mutant in patients with de novo myelodysplastic syndromes: a meta-analysis.
Wang H; Zhang N; Wu X; Zheng X; Ling Y; Gong Y
Ann Hematol; 2019 Dec; 98(12):2629-2639. PubMed ID: 31754743
[TBL] [Abstract][Full Text] [Related]
18. Clinical features and prognosis of patients with myelodysplastic syndromes who were exposed to atomic bomb radiation in Nagasaki.
Matsuo M; Iwanaga M; Kondo H; Soda M; Jo T; Horio K; Takasaki Y; Kawaguchi Y; Tsushima H; Imaizumi Y; Imanishi D; Taguchi J; Sawayama Y; Hata T; Miyazaki Y
Cancer Sci; 2016 Oct; 107(10):1484-1491. PubMed ID: 27487572
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution Experience.
Cooper JP; Khajaviyan S; Smith SD; Maloney DG; Shustov AR; Warren EH; Soma LA; Lynch RC; Ujjani C; Till B; Halpern AB; Gopal AK; Deeg HJ; Scott BL; Shadman M
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):390-395. PubMed ID: 30948330
[TBL] [Abstract][Full Text] [Related]
20. Report on outcomes of hypomethylating therapy for analyzing prognostic value of Revised International Prognostic Scoring System for patients with lower-risk myelodysplastic syndromes.
Lee YJ; Park SW; Lee IH; Ahn JS; Kim HJ; Chung JS; Shin HJ; Lee WS; Lee SM; Joo YD; Kim H; Lee HS; Kim YS; Cho YY; Moon JH; Sohn SK
Ann Hematol; 2016 Oct; 95(11):1795-804. PubMed ID: 27530461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
